Bjørn Myrvang


    Publications 2017

    Lingscheid T, Kurth F, Clerinx J, Marocco S, Trevino B, Schunk M, Muñoz J, Gjørup IE, Jelinek T, Develoux M, Fry G, Jänisch T, Schmid ML, Bouchaud O, Puente S, Zammarchi L, Mørch K, Björkman A, Siikamäki H, Neumayr A, Nielsen H, Hellgren U, Paul M, Calleri G, Kosina P et al. (2017)
    Schistosomiasis in European Travelers and Migrants: Analysis of 14 Years TropNet Surveillance Data
    Am J Trop Med Hyg, 97 (2), 567-574
    DOI 10.4269/ajtmh.17-0034, PubMed 28722637

    Publications 2015

    Myrvang B (2015)
    Manson's tropical diseases
    Tidsskr. Nor. Laegeforen., 135 (2), 158

    Publications 2012

    Mørch K, Myrvang B (2012)
    Treatment of malaria in Norway
    Tidsskr Nor Laegeforen, 132 (6), 664-7
    DOI 10.4045/tidsskr.11.0589, PubMed 22456148

    Publications 2010

    Behrens RH, Carroll B, Hellgren U, Visser LG, Siikamäki H, Vestergaard LS, Calleri G, Jänisch T, Myrvang B, Gascon J, Hatz C (2010)
    The incidence of malaria in travellers to South-East Asia: is local malaria transmission a useful risk indicator?
    Malar J, 9, 266
    DOI 10.1186/1475-2875-9-266, PubMed 20920352

    Myrvang B (2010)
    [A fifth plasmodium that can cause malaria]
    Tidsskr Nor Laegeforen, 130 (3), 282-3
    DOI 10.4045/tidsskr.09.0554, PubMed 20160773

    Publications 2009

    Berhe N, Myrvang B, Gundersen SG (2009)
    Gastro-intestinal symptoms associated with intense Schistosoma mansoni infection affect class-attentiveness of schoolchildren in Ethiopia
    Acta Trop, 110 (1), 52-6
    DOI 10.1016/j.actatropica.2009.01.007, PubMed 19283896

    Publications 2008

    Berhe N, Myrvang B, Gundersen SG (2008)
    Reversibility of schistosomal periportal thickening/fibrosis after praziquantel therapy: a twenty-six month follow-up study in Ethiopia
    Am J Trop Med Hyg, 78 (2), 228-34
    DOI 10.4269/ajtmh.2008.78.228, PubMed 18256420

    Dalgard O, Bjøro K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, Skovlund E, Reichard O, Myrvang B, Sundelöf B, Ritland S, Hellum K, Frydén A, Florholmen J, Verbaan H, North-C Group (2008)
    Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response
    Hepatology, 47 (1), 35-42
    DOI 10.1002/hep.21975, PubMed 17975791

    Jelinek T, Schade Larsen C, Siikamäki H, Myrvang B, Chiodini P, Gascon J, Visser L, Kapaun A, Just-Nübling G (2008)
    European cluster of imported falciparum malaria from Gambia
    Euro Surveill, 13 (51)
    PubMed 19094917

    Newport MJ, Myrvang B (2008)
    Proceedings of a joint meeting between the Norwegian Society of Infectious Diseases and the Royal Society of Tropical Medicine and Hygiene, Oslo, 20 June 2008
    Trans R Soc Trop Med Hyg, 103 (4), 321-4
    DOI 10.1016/j.trstmh.2008.11.010, PubMed 19111872

    Publications 2007

    Behrens RH, Carroll B, Beran J, Bouchaud O, Hellgren U, Hatz C, Jelinek T, Legros F, Mühlberger N, Myrvang B, Siikamäki H, Visser L, TropNetEurop (2007)
    The low and declining risk of malaria in travellers to Latin America: is there still an indication for chemoprophylaxis?
    Malar J, 6, 114
    DOI 10.1186/1475-2875-6-114, PubMed 17716367

    Berhe N, Halvorsen BL, Gundersen TE, Myrvang B, Gundersen SG, Blomhoff R (2007)
    Reduced serum concentrations of retinol and alpha-tocopherol and high concentrations of hydroperoxides are associated with community levels of S. mansoni infection and schistosomal periportal fibrosis in Ethiopian school children
    Am J Trop Med Hyg, 76 (5), 943-9
    DOI 10.4269/ajtmh.2007.76.943, PubMed 17488920

    Berhe N, Myrvang B, Gundersen SG (2007)
    Intensity of Schistosoma mansoni, hepatitis B, age, and sex predict levels of hepatic periportal thickening/fibrosis (PPT/F): a large-scale community-based study in Ethiopia
    Am J Trop Med Hyg, 77 (6), 1079-86
    DOI 10.4269/ajtmh.2007.77.1079, PubMed 18165526

    Storla DG, Rahim Z, Islam MA, Plettner S, Begum V, Myrvang B, Bjune G, Rønnild E, Dahle UR, Mannsåker T (2007)
    Drug resistance of Mycobacterium tuberculosis in the Sunamganj District of Bangladesh
    Scand J Infect Dis, 39 (2), 142-5
    DOI 10.1080/00365540600951242, PubMed 17366031

    Publications 2006

    Damås JK, Jensenius M, Ueland T, Otterdal K, Yndestad A, Frøland SS, Rolain JM, Myrvang B, Raoult D, Aukrust P (2006)
    Increased levels of soluble CD40L in African tick bite fever: possible involvement of TLRs in the pathogenic interaction between Rickettsia africae, endothelial cells, and platelets
    J Immunol, 177 (4), 2699-706
    DOI 10.4049/jimmunol.177.4.2699, PubMed 16888032

    Gjeruldsen S, Loge JH, Myrvang B, Opjordsmoen S (2006)
    Drug addiction in hepatitis C patients leads to a lower quality of life
    Nord J Psychiatry, 60 (2), 157-61
    DOI 10.1080/08039480600583639, PubMed 16635936

    Jensenius M, Fournier PE, Fladby T, Hellum KB, Hagen T, Priø T, Christiansen MS, Vene S, Raoult D, Myrvang B (2006)
    Sub-acute neuropathy in patients with African tick bite fever
    Scand J Infect Dis, 38 (2), 114-8
    DOI 10.1080/00365540500321579, PubMed 16449002

    Nygård K, Brantsaeter A, Feruglio S, Ravn J, Dotevall L, Hasle G, Myrvang B (2006)
    [Histoplasmosis among travellers to Central America]
    Tidsskr Nor Laegeforen, 126 (21), 2838-42
    PubMed 17086244

    Storla DG, Rahim Z, Islam MA, Plettner S, Begum V, Mannsaaker T, Myrvang B, Bjune G, Dahle UR (2006)
    Heterogeneity of Mycobacterium tuberculosis isolates in Sunamganj District, Bangladesh
    Scand J Infect Dis, 38 (8), 593-6
    DOI 10.1080/00365540600606465, PubMed 16857601

    Publications 2005

    Jensenius M, Flaegstad T, Stenstad T, Gjølberg T, Vlatkovic L, Schjøth-Iversen L, Berild D, Bordmann G, Myrvang B (2005)
    Fascioliasis imported to Norway
    Scand J Infect Dis, 37 (6-7), 534-7
    DOI 10.1080/00365540510034518, PubMed 16012024

    Jensenius M, Pretorius AM, Clarke F, Myrvang B (2005)
    Repellent efficacy of four commercial DEET lotions against Amblyomma hebraeum (Acari: Ixodidae), the principal vector of Rickettsia africae in southern Africa
    Trans R Soc Trop Med Hyg, 99 (9), 708-11
    DOI 10.1016/j.trstmh.2005.01.006, PubMed 15993907

    Publications 2004

    Dalgard O, Bjøro K, Hellum KB, Myrvang B, Ritland S, Skaug K, Raknerud N, Bell H (2004)
    Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study
    Hepatology, 40 (6), 1260-5
    DOI 10.1002/hep.20467, PubMed 15558712

    Jelinek T, Myrvang B (2004)
    Surveillance of imported infectious diseases in Europe: report from the 4th TropNetEurop workshop
    Acta Trop, 91 (1), 47-51
    DOI 10.1016/j.actatropica.2004.02.007, PubMed 15158688

    Jensenius M, Fournier PE, Vene S, Ringertz SH, Myrvang B, Raoult D (2004)
    Comparison of immunofluorescence, Western blotting, and cross-adsorption assays for diagnosis of African tick bite fever
    Clin Diagn Lab Immunol, 11 (4), 786-8
    DOI 10.1128/CDLI.11.4.786-788.2004, PubMed 15242958

    Mühlberger N, Jelinek T, Gascon J, Probst M, Zoller T, Schunk M, Beran J, Gjørup I, Behrens RH, Clerinx J, Björkman A, McWhinney P, Matteelli A, Lopez-Velez R, Bisoffi Z, Hellgren U, Puente S, Schmid ML, Myrvang B, Holthoff-Stich ML, Laferl H, Hatz C, Kollaritsch H, Kapaun A, Knobloch J et al. (2004)
    Epidemiology and clinical features of vivax malaria imported to Europe: sentinel surveillance data from TropNetEurop
    Malar J, 3, 5
    DOI 10.1186/1475-2875-3-5, PubMed 15003128

    Rogne Gjeruldsen S, Myrvang B, Opjordsmoen S (2004)
    Criminality in drug addicts: a follow-up study over 25 years
    Eur Addict Res, 10 (2), 49-55
    DOI 10.1159/000076113, PubMed 15004447

    Publications 2003

    Gjeruldsen S, Myrvang B, Opjordsmoen S (2003)
    Risk factors for drug addiction and its outcome. A follow-up study over 25 years
    Nord J Psychiatry, 57 (5), 373-6
    DOI 10.1080/08039480310002714, PubMed 14522611

    Gjeruldsen SR, Myrvang B, Opjordsmoen S (2003)
    A 25-year follow-up study of drug addicts hospitalised for acute hepatitis: present and past morbidity
    Eur Addict Res, 9 (2), 80-6
    DOI 10.1159/000068805, PubMed 12644734

    Grobusch MP, Mühlberger N, Jelinek T, Bisoffi Z, Corachán M, Harms G, Matteelli A, Fry G, Hatz C, Gjørup I, Schmid ML, Knobloch J, Puente S, Bronner U, Kapaun A, Clerinx J, Nielsen LN, Fleischer K, Beran J, da Cunha S, Schulze M, Myrvang B, Hellgren U (2003)
    Imported schistosomiasis in Europe: sentinel surveillance data from TropNetEurop
    J Travel Med, 10 (3), 164-9
    DOI 10.2310/7060.2003.35759, PubMed 12757691

    Jensenius M, Fournier PE, Hellum KB, Wesslén L, Caruso G, Priø T, Løhne K, Vene S, Raoult D, Myrvang B (2003)
    Sequential changes in hematologic and biochemical parameters in African tick bite fever
    Clin Microbiol Infect, 9 (7), 678-83
    DOI 10.1046/j.1469-0691.2003.00713.x, PubMed 12925109

    Jensenius M, Fournier PE, Kelly P, Myrvang B, Raoult D (2003)
    African tick bite fever
    Lancet Infect Dis, 3 (9), 557-64
    DOI 10.1016/s1473-3099(03)00739-4, PubMed 12954562

    Jensenius M, Fournier PE, Vene S, Hoel T, Hasle G, Henriksen AZ, Hellum KB, Raoult D, Myrvang B, Norwegian African Tick Bite Fever Study Group (2003)
    African tick bite fever in travelers to rural sub-Equatorial Africa
    Clin Infect Dis, 36 (11), 1411-7
    DOI 10.1086/375083, PubMed 12766836

    Jensenius M, Ueland T, Fournier PE, Brosstad F, Stylianou E, Vene S, Myrvang B, Raoult D, Aukrust P (2003)
    Systemic inflammatory responses in African tick-bite fever
    J Infect Dis, 187 (8), 1332-6
    DOI 10.1086/368415, PubMed 12696016

    Mühlberger N, Jelinek T, Behrens RH, Gjørup I, Coulaud JP, Clerinx J, Puente S, Burchard G, Gascon J, Grobusch MP, Weitzel T, Zoller T, Kollaritsch H, Beran J, Iversen J, Hatz C, Schmid ML, Björkman A, Fleischer K, Bisoffi Z, Guggemos W, Knobloch J, Matteelli A, Schulze MH, Laferl H et al. (2003)
    Age as a risk factor for severe manifestations and fatal outcome of falciparum malaria in European patients: observations from TropNetEurop and SIMPID Surveillance Data
    Clin Infect Dis, 36 (8), 990-5
    DOI 10.1086/374224, PubMed 12684911

    Publications 2002

    Bell H, Dalgard O, Bjøro K, Hellum KB, Myrvang B (2002)
    [Treatment of chronic hepatitis C]
    Tidsskr Nor Laegeforen, 122 (9), 926-8
    PubMed 12082838

    Bjøro K, Bell H, Hellum KB, Skaug K, Raknerud N, Sandvei P, Døskeland B, Maeland A, Lund-Tønnesen S, Myrvang B (2002)
    Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study
    Scand J Gastroenterol, 37 (2), 226-32
    DOI 10.1080/003655202753416920, PubMed 11843062

    Bjøro K, Bell H, Myrvang B, Skaug K, Raknerud N, Sandvei P, Størseth S, Ritland S, Lund-Tønnesen S, Bucher A, Hellum KB (2002)
    Effect of interferon-alpha induction therapy on genotype 2b/3a and low viral load hepatitis C virus infection. A randomized multicentre study
    Scand J Gastroenterol, 37 (3), 344-9
    DOI 10.1080/003655202317284264, PubMed 11916198

    Dalgard O, Bjøro K, Hellum K, Myrvang B, Bjøro T, Haug E, Bell H (2002)
    Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy
    J Intern Med, 251 (5), 400-6
    DOI 10.1046/j.1365-2796.2002.00974.x, PubMed 11982739

    Dalgard O, Bjøro K, Hellum K, Myrvang B, Skaug K, Gutigard B, Bell H, Construct Group (2002)
    Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up
    Eur Addict Res, 8 (1), 45-9
    DOI 10.1159/000049487, PubMed 11818693

    Distante S, Bjøro K, Hellum KB, Myrvang B, Berg JP, Skaug K, Raknerud N, Bell H (2002)
    Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection
    Liver, 22 (3), 269-75
    DOI 10.1046/j.0106-9543.2002.01672.x, PubMed 12100578

    Dunlop O, Bjørklund R, Bruun JN, Evensen R, Goplen AK, Liestøl K, Sannes M, Maehlen J, Myrvang B (2002)
    Early psychomotor slowing predicts the development of HIV dementia and autopsy-verified HIV encephalitis
    Acta Neurol Scand, 105 (4), 270-5
    DOI 10.1034/j.1600-0404.2002.9o188.x, PubMed 12004769

    Gjeruldsen S, Myrvang B (2002)
    Hepatitis B virus infection in drug addicts: no acute fatalities, no chronicity and could have benefits
    APMIS, 110 (9), 620-4
    DOI 10.1034/j.1600-0463.2002.1100904.x, PubMed 12529014

    Jelinek T, Mühlberger N, Harms G, Corachán M, Grobusch MP, Knobloch J, Bronner U, Laferl H, Kapaun A, Bisoffi Z, Clerinx J, Puente S, Fry G, Schulze M, Hellgren U, Gjørup I, Chalupa P, Hatz C, Matteelli A, Schmid M, Nielsen LN, da Cunha S, Atouguia J, Myrvang B, Fleischer K et al. (2002)
    Epidemiology and clinical features of imported dengue fever in Europe: sentinel surveillance data from TropNetEurop
    Clin Infect Dis, 35 (9), 1047-52
    DOI 10.1086/342906, PubMed 12384837

    Jensenius M, Hoel T, Raoult D, Fournier PE, Kjelshus H, Bruu AL, Myrvang B (2002)
    Seroepidemiology of Rickettsia africae infection in Norwegian travellers to rural Africa
    Scand J Infect Dis, 34 (2), 93-6
    DOI 10.1080/00365540110077029, PubMed 11928860

    Myrvang B, von der Lippe B (2002)
    [African trypanosomiasis--a rare imported disease]
    Tidsskr Nor Laegeforen, 122 (1), 33-4
    PubMed 11851292

    Strand EA, Strand ØA, Hellum KB, Smith-Erichsen N, Myrvang B (2002)
    [A young, stuporous and afebrile man with icterus and nosebleed]
    Tidsskr Nor Laegeforen, 122 (6), 619-23
    PubMed 11998715

    Publications 2001

    Gjeruldsen S, Abdelnoor M, Opjordsmoen S, Myrvang B (2001)
    Death rates and causes of death in cohorts of serum hepatitis patients followed up for more than 20 years
    Epidemiol Infect, 126 (1), 89-96
    DOI 10.1017/s0950268801005064, PubMed 11293686

    Publications 2000

    Brubakk O, Myrvang B (2000)
    [Non-practical guidelines?]
    Tidsskr Nor Laegeforen, 120 (26), 3196
    PubMed 11109372

    Liestøl K, Kvittingen EA, Rootwelt H, Dunlop O, Goplen AK, Pedersen JC, Brorson SH, Børresen-Dale AL, Myrvang B, Maehlen J (2000)
    Association between apolipoprotein E genotypes and cancer risk in patients with acquired immunodeficiency syndrome
    Cancer Detect Prev, 24 (5), 496-9
    PubMed 11129992

    Myrvang B (2000)
    [Malaria in Norway--diagnosis, treatment and prevention]
    Tidsskr Nor Laegeforen, 120 (14), 1648-52
    PubMed 10901075

    Myrvang B, Godal T (2000)
    [WHO's malaria program Roll Back Malaria]
    Tidsskr Nor Laegeforen, 120 (14), 1661-4
    PubMed 10901078

    Mørk C, Kalgaard OM, Myrvang B, Kvernebo K (2000)
    Erythromelalgia in a patient with AIDS
    J Eur Acad Dermatol Venereol, 14 (6), 498-500
    DOI 10.1046/j.1468-3083.2000.00145.x, PubMed 11444274

    Rønning EJ, Myrvang B, Jensenius M (2000)
    [Falciparum malaria in Oslo and Akerhus]
    Tidsskr Nor Laegeforen, 120 (14), 1658-60
    PubMed 10901077

    Publications 1999

    Bell H, Hellum K, Harthug S, Myrvang B, Ritland S, Maeland A, von der Lippe B, Bjøro K, Skaug K, Gutigard BG, Raknerud N, Simmonds P (1999)
    Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group
    Scand J Gastroenterol, 34 (2), 194-8
    DOI 10.1080/00365529950173087, PubMed 10192200

    Hem E, Small T, Opjordsmoen S, Myrvang B (1999)
    [Neurosyphilis--still a relevant differential diagnosis]
    Tidsskr Nor Laegeforen, 119 (17), 2469-71
    PubMed 10425898

    Jensenius M, Hasle G, Henriksen AZ, Vene S, Raoult D, Bruu AL, Myrvang B (1999)
    African tick-bite fever imported into Norway: presentation of 8 cases
    Scand J Infect Dis, 31 (2), 131-3
    DOI 10.1080/003655499750006155, PubMed 10447320

    Jensenius M, Rønning EJ, Blystad H, Bjørneklett A, Hellum KB, Bucher A, Håheim LL, Myrvang B (1999)
    Low frequency of complications in imported falciparum malaria: a review of 222 cases in south-eastern Norway
    Scand J Infect Dis, 31 (1), 73-8
    DOI 10.1080/00365549950161925, PubMed 10381222

    Tangen JM, Berentsen S, Dahl IM, Ly B, Myrvang B (1999)
    [Empirical antibiotic treatment of patients with acute myelogenous leukemia]
    Tidsskr Nor Laegeforen, 119 (1), 35-8
    PubMed 10025202

    Publications 1998

    Jarvis LM, Bell H, Simmonds P, Hawkins A, Hellum K, Harthug S, Maeland A, Ritland S, Myrvang B, von der Lippe B, Raknerud N, Skaug K (1998)
    The effect of treatment with alpha-interferon on hepatitis G/GBV-C viraemia. The CONSTRUCT Group
    Scand J Gastroenterol, 33 (2), 195-200
    DOI 10.1080/00365529850166941, PubMed 9517532

    Jensenius M, Myrvang B (1998)
    [Imported fever]
    Tidsskr Nor Laegeforen, 118 (3), 402-6
    PubMed 9499729

    Jensenius M, Myrvang B (1998)
    [Imported fever. A diagnostic challenge]
    Nord Med, 113 (4), 107-11
    PubMed 9579092

    Jensenius M, Myrvang B, Størvold G, Bucher A, Hellum KB, Bruu AL (1998)
    Herpes simplex virus type 2 DNA detected in cerebrospinal fluid of 9 patients with Mollaret's meningitis
    Acta Neurol Scand, 98 (3), 209-12
    DOI 10.1111/j.1600-0404.1998.tb07296.x, PubMed 9786620

    Lundin KE, Selbekk BH, Myrvang B, Løberg EM (1998)
    [Cytomegalovirus as the cause of toxic dilatation of the colon]
    Tidsskr Nor Laegeforen, 118 (21), 3277-9
    PubMed 9772815

    Publications 1997

    Bell H, Hellum K, Harthug S, Maeland A, Ritland S, Myrvang B, von der Lippe B, Raknerud N, Skaug K, Gutigard BG, Skjaerven R, Prescott LE, Simmonds P (1997)
    Genotype, viral load and age as independent predictors of treatment outcome of interferon-alpha 2a treatment in patients with chronic hepatitis C. Construct group
    Scand J Infect Dis, 29 (1), 17-22
    DOI 10.3109/00365549709008658, PubMed 9112292

    Dunlop O, Goplen AK, Liestøl K, Myrvang B, Rootwelt H, Christophersen B, Kvittingen EA, Maehlen J (1997)
    HIV dementia and apolipoprotein E
    Acta Neurol Scand, 95 (5), 315-8
    DOI 10.1111/j.1600-0404.1997.tb00217.x, PubMed 9188909

    Gundersen SG, Rostrup M, von der Lippe E, Platou ES, Myrvang B, Edwards G (1997)
    Halofantrine-associated ventricular fibrillation in a young woman with no predisposing QTc prolongation
    Scand J Infect Dis, 29 (2), 207-8
    DOI 10.3109/00365549709035889, PubMed 9181664

    Jensenius M, Myrvang B, Størvold G (1997)
    [Serous meningitis associated with primary genital herpes infection]
    Tidsskr Nor Laegeforen, 117 (16), 2316-8
    PubMed 9265274

    Jenseuius M, Myrvang B, Størvold G (1997)
    [Mollaret meningitis. Is the riddle finally solved?]
    Tidsskr Nor Laegeforen, 117 (16), 2319-21
    PubMed 9265275

    Myrvang B (1997)
    [Malaria in Norway]
    Tidsskr Nor Laegeforen, 117 (7), 984-5
    PubMed 9103014

    Publications 1996

    Bell H, Hellum K, Harthug S, Maeland A, Ritland S, Myrvang B, von der Lippe B, Raknerud N, Skaug K, Prescott L, Simmonds P (1996)
    Prevalence of hepatitis C genotypes among patients with chronic hepatitis C in Norway. Construct Group
    Scand J Infect Dis, 28 (4), 357-9
    DOI 10.3109/00365549609037919, PubMed 8893398

    Dunlop O, Rootwelt V, Sannes M, Goplen AK, Abdelnoor M, Skaug K, Baklien K, Skar A, Melby K, Myrvang B, Bruun JN (1996)
    Risk of toxoplasmic encephalitis in AIDS patients: indications for prophylaxis
    Scand J Infect Dis, 28 (1), 71-3
    DOI 10.3109/00365549609027153, PubMed 9122637

    Schrumpf E, Bjøro K, Bell H, Harthug S, Hellum KB, Myrvang B, Maeland A, Ritland S (1996)
    [Treatment of hepatitis C]
    Tidsskr Nor Laegeforen, 116 (15), 1792-4
    PubMed 8693463

    Publications 1995

    Gundersen SG, Myrvang B (1995)
    [Specific intracranial infections]
    Tidsskr Nor Laegeforen, 115 (19), 2434
    PubMed 7667862

    Myrvang B (1995)
    Mycobacterial infections in Norway
    Scand J Infect Dis Suppl, 98, 12-4
    PubMed 8867170

    Myrvang B (1995)
    Mycobacterial infections in Norway
    Scand. J. Infect. Dis. (98), 12-14

    Publications 1993

    Dunlop O, Bjørklund R, Abdelnoor M, Myrvang B (1993)
    Total reaction time: a new approach in early HIV encephalopathy?
    Acta Neurol Scand, 88 (5), 344-8
    DOI 10.1111/j.1600-0404.1993.tb05355.x, PubMed 8296533

    Publications 1992

    Dunlop O, Bjørklund RA, Abdelnoor M, Myrvang B (1992)
    Five different tests of reaction time evaluated in HIV seropositive men
    Acta Neurol Scand, 86 (3), 260-6
    DOI 10.1111/j.1600-0404.1992.tb05082.x, PubMed 1414244

    Dunlop O, Myrvang B, Bjørklund R (1992)
    Neuropsychological tests in HIV
    Neurology, 42 (10), 2055-6
    DOI 10.1212/wnl.42.10.2055-c, PubMed 1407598

    Publications 1991

    Dunlop O, Bruun JN, Myrvang B, Fagerhol MK (1991)
    Calprotectin in cerebrospinal fluid of the HIV infected: a diagnostic marker of opportunistic central nervous system infection?
    Scand J Infect Dis, 23 (6), 687-9
    DOI 10.3109/00365549109024294, PubMed 1815329

    Midtvedt K, Myrvang B (1991)
    [Antibiotic prevention in permanent pacemaker implantation in Norway]
    Tidsskr Nor Laegeforen, 111 (9), 1106-7
    PubMed 2024255

    Publications 1983

    Linnestad P, Myrvang B, Ritland S, Bergan A, Valnes K, Holst JJ (1983)
    [Glucagon producing tumors of the pancreas. A case report and literature review]
    Tidsskr Nor Laegeforen, 103 (22), 1520-2
    PubMed 6314588

    Myrvang B (1983)
    [What role does the immune apparatus play in the defense against fungal infections?]
    Tidsskr Nor Laegeforen, 103 (3), 182-3
    PubMed 6845311

    Myrvang B (1983)
    [Skin tests as a diagnostic aid in infectious diseases]
    Tidsskr Nor Laegeforen, 103 (3), 201-3
    PubMed 6845321

    Myrvang B (1983)
    [Gammaglobulin replacement therapy - indications and realization]
    Tidsskr Nor Laegeforen, 103 (3), 219-22
    PubMed 6189243

    Myrvang B (1983)
    [Immunological studies in the diagnosis of imported parasitic diseases]
    Tidsskr Nor Laegeforen, 103 (3), 211-3
    PubMed 6845324

    Myrvang B (1983)
    [Pneumococcal vaccine - characteristics and indications]
    Tidsskr Nor Laegeforen, 103 (3), 226-8
    PubMed 6845327

    Publications 1982

    Melsom R, Harboe M, Myrvang B, Godal T, Belehu A (1982)
    Immunoglobulin class specific antibodies to M. leprae in leprosy patients, including the indeterminate group and healthy contacts as a step in the development of methods for sero-diagnosis of leprosy
    Clin Exp Immunol, 47 (2), 225-33
    PubMed 7042137

    Publications 1975

    Myrvang B (1975)
    Immune responses to mycobacterium leprae in man
    J Oslo City Hosp, 25 (1), 3-24
    PubMed 1092818

    Publications 1974

    Bull. Inst. Pasteur, 72 (3), 273-310

    Myrvang B (1974)
    Immune responsiveness to Mycobacterium leprae of healthy humans. Application of the leucocyte migration inhibition test
    Acta Pathol Microbiol Scand B Microbiol Immunol, 82B (5), 707-14
    DOI 10.1111/j.1699-0463.1974.tb00239.x, PubMed 4611138

    Myrvang B, Feek CM, Godal T (1974)
    Antimycobacterial antibodies in sera from patients throughout the clinico-pathological disease spectrum of leprosy
    Acta Pathol Microbiol Scand B Microbiol Immunol, 82B (5), 701-6
    DOI 10.1111/j.1699-0463.1974.tb00238.x, PubMed 4215284

    Publications 1973

    Godal T, Myrvang B, Samuel DR (1973)
    [Leprosy as an immunological model]
    Tidsskr Nor Laegeforen, 93 (4), 217-22
    PubMed 4570661

    Godal T, Myrvang B, Samuel DR, Ross WF, Lofgren M (1973)
    Mechanism of "reactions" in borderline tuberculoid (BT) leprosy. A preliminary report
    Acta Pathol Microbiol Scand Suppl, 236 (0), 45-53
    PubMed 4602874

    Myrvang B (1973)
    The immunological spectrum of leprosy
    Ethiop Med J, 11 (2), 188-9
    PubMed 4596876

    Myrvang B, Godal T, Feek CM, Ridley DS, Samuel DR (1973)
    Immune response to Mycobacterium leprae in indeterminate leprosy patients
    Acta Pathol Microbiol Scand B Microbiol Immunol, 81 (5), 615-20
    DOI 10.1111/j.1699-0463.1973.tb02251.x, PubMed 4209177

    Myrvang B, Godal T, Ridley DS, Fröland SS, Song YK (1973)
    Immune responsiveness to Mycobacterium leprae and other mycobacterial antigens throughout the clinical and histopathological spectrum of leprosy
    Clin Exp Immunol, 14 (4), 541-53
    PubMed 4583777

    Samuel DR, Godal T, Myrvang B, Song YK (1973)
    Behavior of Mycobacterium leprae in human macrophages in vitro
    Infect Immun, 8 (3), 446-9
    PubMed 4581011

    Thorsby E, Godal T, Myrvang B (1973)
    HL-A antigens and susceptibility to diseases. II. Leprosy
    Tissue Antigens, 3 (5), 373-7
    DOI 10.1111/j.1399-0039.1973.tb00506.x, PubMed 4771178

    Publications 1972

    Godal T, Myrvang B, Froland SS, Shao J, Melaku G (1972)
    Evidence that the mechanism of immunological tolerance ("central failure") is operative in the lack of host resistance in lepromatous leprosy
    Scand J Immunol, 1 (4), 311-21
    DOI 10.1111/j.1365-3083.1972.tb03296.x, PubMed 4590279

    Publications 1971

    Godal T, Myklestad B, Samuel DR, Myrvang B (1971)
    Characterization of the cellular immune defect in lepromatous leprosy: a specific lack of circulating Mycobacterium leprae-reactive lymphocytes
    Clin Exp Immunol, 9 (6), 821-31
    PubMed 4945738

    Sudarsanam A, Grabosz J, Myklestad B, Myrvang B, Harboe M (1971)
    Experimental Arthus reactions using the same antigen in soluble and corpuscular form
    Afr J Med Sci, 2 (4), 319-28
    PubMed 4255853

    Page visits: 3486